BioTime, Inc. and the California Institute for Regenerative Medicine Sign Distribution Agreement for GMP-Compliant Human Embryonic Stem Cell Lines ALAMEDA, Calif ...
BioTime, Inc. announced an agreement with the California Institute for Regenerative Medicine (CIRM) to make five clinical-grade human Embryonic Stem (hES) cell lines available to California-based ...
BioTime and OncoCyte Corporation Publish Data on the Gene as a Marker and Potential Diagnostic for a Wide Array of Human Cancers BioTime, Inc.Peter Garcia, 510-521-3390 ext. 367Chief Financial ...
BioTime also has significant equity holdings in two publicly traded companies, Asterias Biotherapeutics, Inc. (NYSE American: AST) and OncoCyte Corporation (NYSE American: OCX), and a private company, ...
BioTime Signs Definitive Agreement With Geron Regarding Stem Cell Assets Investor Commits to $10 Million Financing ALAMEDA, Calif.--(BUSINESS WIRE)-- BioTime, Inc. (NYSE MKT: BTX) and its recently ...
With Ocata Therapeutics being acquired by Astellas Pharma, a very similar company based on its therapeutic stem cell platform and IP, BioTime, Inc., could be next. Japan's recent legislation has ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback